<img src="https://ml.globenewswire.com/Resource/Download/908fb457-7f8e-4a08-9081-5565e3dfb3d7?size=2" nborder="0" align="left" hspace="5" vspace="5" title="22157.jpg" alt="Company Logo"/>Dublin, July 20, 2026 <a href="https://www.globenewswire.com" target="_blank">(GLOBE NEWSWIRE)</a> -- The <a href="https://www.researchandmarkets.com/reports/2300209/companion_diagnostic_collaboration_and_licensing?utm_source=GNE&amp;utm_medium=PressRelease&amp;utm_code=jc9hmg&amp;utm_campaign=2307485+-+Companion+Diagnostic+Collaboration+and+Licensing+Deals%2c+2010-2026+-+Analyze+560%2b+Diagnostic+Partnerships%3b+Compare+Upfronts%2c+Milestones+and+Royalties&amp;utm_exec=jocamsai" rel="nofollow" target="_blank" title="Companion Diagnostic Collaboration and Licensing Deals 2010-2026">"Companion Diagnostic Collaboration and Licensing Deals 2010-2026"</a> has been added to ResearchAndMarkets.com's offering. This report provides a comprehensive and structured analysis of 560+ companion diagnostic collaboration and licensing deals, delivering a clear and evidence-based view of how partnerships are designed, negotiated, and executed across the market. The definitive benchmark for companion diagnostic dealmaking Companion diagnostic partnering is driven by the integration of diagnostics with therapeutic development, with deal structures reflecting co-development strategies, regulatory alignment, and precision medicine approaches. Establish a clear view of market standards The report enables a precise understanding of how companion diagnostic deals are structured in practice, allowing you to: <ul><li>Benchmark comparable transactions with confidence</li><li>Detailed analysis of upfronts, milestones, and royalty structures across relevant deals</li><li>Define realistic market parameters</li><li>Clear insight into how deal terms vary by technology type, therapeutic alignment, and partner profile</li><li>Support valuation and structuring decisions with evidence</li><li>Ground internal discussions in real transaction data rather than assumptions</li><li>Understand how leading companies approach dealmaking</li><li>Visibility into partner behaviour and recurring deal structures across a precision medicine-driven and co-development-focused landscape</li></ul> Designed for real-world BD and strategy use The report is widely used to: <ul><li>Structure and benchmark diagnostic-therapeutic partnerships</li><li>Prepare for negotiations with well-defined market context</li><li>Evaluate co-development and licensing opportunities</li><li>Support internal strategy with robust, defensible data</li></ul> What's included? <ul><li>560+ companion diagnostic collaboration and licensing deals</li><li>Financial terms, including upfronts, milestones, and royalties where disclosed</li><li>Fully searchable deal directory (by company, technology, and therapeutic alignment)</li><li>Direct access to SEC-filed agreements and source documents</li><li>Analysis of deal trends, key transactions, and active dealmakers</li><li>A trusted, evidence-based reference for companion diagnostic dealmaking</li></ul> Combining comprehensive deal coverage with contract-level insight, this report provides a trusted, evidence-based reference for how companion diagnostic partnerships are structured, negotiated, and valued. Companies Featured <ul><li>2cureX</li><li>Abbott Laboratories</li><li>Acrivon Therapeutics</li><li>Agilent Technologies</li><li>Akoya Biosciences</li><li>Allarity Therapeutics</li><li>Amgen</li><li>AnchorDx</li><li>Arvinas</li><li>AstraZeneca</li><li>Bayer</li><li>BeiGene</li><li>Biocartis</li><li>BioNTech</li><li>Blueprint Medicines</li><li>Burning Rock</li><li>Caris Life Sciences</li><li>Celldex Therapeutics</li><li>Chugai Pharmaceutical</li><li>Clovis Oncology</li><li>ConcertAI</li><li>Daiichi Sankyo</li><li>Denovo Biopharma</li><li>Eisai</li><li>Epic Sciences</li><li>Evotec</li><li>Foundation Medicine</li><li>Freenome</li><li>Genentech</li><li>Grail</li><li>Guardant Health</li><li>Illumina</li><li>Incyte</li><li>Janssen Biotech</li><li>Karyopharm Therapeutics</li><li>Loxo Oncology</li><li>Merck KGaA</li><li>Myriad Genetics</li><li>Natera</li><li>Novartis</li><li>PathAI</li><li>Pfizer</li><li>QIAGEN</li><li>Roche Diagnostics</li><li>Sanofi</li><li>Seegene</li><li>Tempus</li><li>Thermo Fisher Scientific</li><li>Vertex Pharmaceuticals</li><li>ZAI Laboratory</li></ul> For more information about this report visit <a href="https://www.researchandmarkets.com/reports/2300209/companion_diagnostic_collaboration_and_licensing?utm_source=GNE&amp;utm_medium=PressRelease&amp;utm_code=jc9hmg&amp;utm_campaign=2307485+-+Companion+Diagnostic+Collaboration+and+Licensing+Deals%2c+2010-2026+-+Analyze+560%2b+Diagnostic+Partnerships%3b+Compare+Upfronts%2c+Milestones+and+Royalties&amp;utm_exec=jocamsai" rel="nofollow" target="_blank" title="">https://www.researchandmarkets.com/r/fa82zr</a> About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. <pre>CONTACT: 
CONTACT: ResearchAndMarkets.com 
 Laura Wood,Senior Press Manager 
 press@researchandmarkets.com
 For E.S.T Office Hours Call 1-917-300-0470 
 For U.S./ CAN Toll Free Call 1-800-526-8630 
 For GMT Office Hours Call +353-1-416-8900 

</pre> <img alt="" src='https://ml.globenewswire.com/media/YmE1OWNjYWUtZTdiNS00MjgwLWEzMDktNTg4OTkwMzQ1ZTJiLTEwMjY3MzctMjAyNi0wNy0yMC1lbg==/tiny/Research-and-Markets.png' referrerpolicy='no-referrer-when-downgrade' />

GlobeNewswire Inc.

Companion Diagnostic Collaboration and Licensing Deals, 2010-2026 - Analyze 560+ Diagnostic Partnerships; Compare Upfronts, Milestones and Royalties

Latest news from the world of business and finance – both local and global

MONEY FM 89.3 is Singapore's first and only Business and Personal Finance station, featuring local and international business and financial news.

MONEY FM 89.3

Discover newsletters from our DJs on LinkedIn